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Abstract
Background:  Magnetic resonance cholangiopancreatography (MRCP) is an alternative to
diagnostic endoscopic retrograde cholangiopancreatography (ERCP) for investigating biliary
obstruction. The use of MRCP, a non-invasive procedure, may prevent the use of unnecessary
invasive procedures. The aim of the study was to compare the findings of MRCP with those of
ERCP by the computation of accuracy statistics.
Methods:  Thirteen electronic bibliographic databases, covering biomedical, science, health
economics and grey literature were searched. A systematic review of studies comparing MRCP to
diagnostic ERCP in patients with suspected biliary obstruction was conducted. Sensitivity,
specificity, likelihood ratios, acceptability and adverse events were reported.
Results: 25 studies were identified reporting several conditions including choledocholithiasis (18
studies), malignancy (four studies), obstruction (three studies), stricture (two studies) and
dilatation (five studies). Three of the 18 studies reporting choledocholithiasis were excluded from
the analysis due to lack of data, or differences in study design. The sensitivity for the 15 studies of
choledocholithiasis ranged from 0.50 to 1.00 while specificity ranged from 0.83 to 1.00. The
positive likelihood ratio ranged: from 5.44–47.72 and the negative likelihood ratio for the 15 studies
ranged from 0.00–0.51. Significant heterogeneity was found across the 15 studies so the sensitivities
and specificities were summarised by a Receiver Operating Characteristic (ROC) curve. For
malignancy, sensitivity ranged from 0.81 to 0.94 and specificity from 0.92 to 1.00. Positive likelihood
ratios ranged from 10.12 to 43 and negative likelihood ratios ranged from 0.15 to 0.21, although
these estimates were less reliable.
Conclusion: MRCP is a comparable diagnostic investigation in comparison to ERCP for diagnosing
biliary obstruction.
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Background
Biliary obstruction may be due to a variety of causes
including choledocholithiasis, tumours, and trauma,
including injury after gall bladder surgery, with choledo-
colithiasis being the most common cause. The prevalence
of gallstones in England and Wales was 182 per 10,000
person years at risk. The incidence rate was 8 per 10,000
person years at risk for 1991–1992 [1]. Patients with sus-
pected biliary obstruction present with abnormal liver
function and symptoms such as jaundice, pale-coloured
stools, dark urine, itching, abdominal pain in the upper
right quadrant, fever, nausea and vomiting. Endoscopic
ultrasonography (EUS) is the first-line imaging investiga-
tion in patients with jaundice or right upper-quadrant
pain [2]. Although EUS is non-invasive, quick and inex-
pensive it is very operator and patient dependent.
Endoscopic retrograde cholangiopancreatography (ERCP)
is currently the 'gold standard' for the diagnosis of biliary
obstruction. It is one of several invasive direct cholangiog-
raphy techniques. However, it is an imperfect diagnostic
tool and other procedures may be more appropriate gold
standards for diagnosis in the future [3]. Magnetic reso-
nance cholangiopancreatography (MRCP) is an alterna-
tive to diagnostic ERCP for imaging the biliary tree and
investigating biliary obstruction. MRCP was developed in
1991 and techniques are continuing to improve. A major
feature of MRCP is that it is not a therapeutic procedure,
while in contrast ERCP is used for both diagnosis and
treatment. MRCP also does not have the small but definite
morbidity and mortality associated with ERCP. The use of
MRCP in diagnosing biliary obstruction may avoid the
use of unnecessary invasive procedures such as ERCP.
Indications for the use of MRCP include: unsuccessful or
contraindicated ERCP; patient preference for non-invasive
imaging; patients considered to be at low risk of having
pancreatic or biliary disease; patients where the need for
therapeutic ERCP is considered unlikely; and those with a
suspected neoplastic cause for pancreatic or biliary
obstruction [4]. No patient preparation is required for
MRCP and sedation is not usually required. MRCP is par-
ticularly useful where ERCP is difficult, hazardous or
impossible. It is also an important option for patients
with failed ERCPs. ERCP and MRCP have different con-
traindications allowing them to be used as complemen-
tary techniques.
In order to determine the sensitivity and specificity of
MRCP compared to ERCP, a systematic review was under-
taken to identify all relevant studies comparing the two
techniques using clearly defined inclusion and exclusion
criteria. This paper therefore compares the findings of
MRCP with diagnostic ERCP for the investigation of bil-
iary obstruction, using accuracy statistics. We also report
study quality, population characteristics and suspected
conditions. The paper summarises the key clinical points
reported in a recent Health Technology Assessment Mon-
ograph [5]. Since the most common cause of biliary
obstruction is choledocholithiasis, we have concentrated
mainly on the diagnosis of this condition.
Methods
We searched 13 electronic databases Medline, Embase
and the Cochrane Controlled Trials Register from incep-
tion to January 2003. Reference lists of relevant articles
were hand searched and various health services research-
related resources were consulted via the Internet. Search
terms included population search terms such as biliary,
biliary tract, bile, gallbladder, choledocholithiasis and
were combined with intervention terms such as magnetic
resonance imaging, MRI and non-invasive diagnostic
imaging. The search strategy is described in detail else-
where [5]. No language or study/publication-type restric-
tions were applied to the searches. Inclusion criteria were
adult patients with suspected biliary obstruction or dilata-
tion, as defined by the individual studies, having MRCP
and ERCP for diagnostic purposes. Outcome measures
included sensitivity, specificity and likelihood ratios in
different patient groups, acceptability to patients and
adverse effects. The ERCP test results were assumed to be
a true 'gold standard' diagnosis, although even the results
of this test may be subject to error and thus not represent
the patient's true condition. Only English language papers
were selected. Studies involving pancreatic ductal system
abnormalities were excluded, as were those not including
a comparison of MRCP with diagnostic ERCP. Other
exclusion criteria were: papers published before 1995;
comparison of MRCP with failed or unsuccessful ERCP;
studies where MRCP results informed decision to proceed
to ERCP; and retrospective study design. Excluded studies
were documented together with reasons for exclusion [5].
Data was extracted by one researcher using a standardised
data extraction form and checked by another. Full details
of the review process are described elsewhere [5].
The studies were assessed using quality criteria for diag-
nostic or screening tests [6]. These criteria include 14 com-
ponents of study quality such as: appropriate spectrum of
patients, selection criteria, independent assessment of test
results, verification bias (whether all patients had both
tests), reporting of uninterpretable results and withdraw-
als among others.
Standard tests for heterogeneity were conducted [7]. Point
estimates and 95% confidence intervals for summary sta-
tistics (sensitivity, specificity, likelihood ratio) were calcu-
lated for each study and presented graphically with forest
plots. In meta-analyses of diagnostic results one must also
consider variation introduced by changes in the diagnos-BMC Medical Imaging 2006, 6:9 http://www.biomedcentral.com/1471-2342/6/9
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tic threshold; studies may use different thresholds to
define positive and negative test results. In the event of
heterogeneity and/or variation in the diagnostic thresh-
old, studies were summarised graphically with a Summary
Receiver Operating Characteristic curve (SROC) curve and
via the Littenberg and Moses (L-M) method for estimation
of a best fitting SROC curve [8]. The L-M method consists
of linear regression of the log diagnostic odds ratio, D,
against the log of the measure of diagnostic threshold S,
to produce estimates of the parameters a and b from the
regression equation, D = a + bS. D and S are calculated
from the true positive and false positive rates. We com-
puted the sensitivity and specificity values from the SROC
at the mean, minimum and maximum values of the S
parameter, to indicate a central value and associated band
with which the data were compatible.
Results
Out of a total of 1437 potentially relevant studies, 28
studies were identified that directly compared MRCP with
diagnostic ERCP [9-36]. An additional study was identi-
fied that covered patient satisfaction [37]. Study selection
is outlined in Figure 1. The quality of studies was variable.
Results are shown in Table 1.
In only one study did all selected patients have both
MRCP and diagnostic ERCP [31], indicating potential ver-
ification bias. Thirteen studies [10-12,14,15,17,18,25,28-
30,34,36] reported adequate blinding and only six
[10,18,22,27,29,34] reported information on agreement
of MRCP results for more than one investigator. Nine
studies [10,12,17,20,22,25,28,29,32] gave no informa-
tion on other diagnostic tests and most studies did not
adequately report inclusion and exclusion criteria.
Seven studies [9,17,21,22,25,26,34], reported results
comparing MRCP to final diagnosis (including ERCP and
other test results) but only four of these reported data
comparing MRCP with final diagnosis and ERCP with
final diagnosis. The remaining 21 reported results com-
paring MRCP with diagnostic ERCP. Three [10,17,19] of
the 28 studies did not provide enough information to cal-
culate sensitivity, specificity and likelihood ratios. Accu-
racy was assessed separately for each condition
(choledocolithiasis, malignancy, dilatation, obstruction
and stricture). The results of the remaining 25 studies are
shown in Table 2. Table 3 describes study characteristics.
Studies comparing MRCP and ERCP with final diagnosis
are shown in Table 4.
Assessment of effectiveness by condition: 
choledocolithiasis
One of the most common causes of biliary obstruction is
choledocolithiasis: indeed 18 out of the 28 studies (64%)
were for this condition. For this reason we concentrate
mainly on the analysis of these studies. Of the 18 studies
reporting results for choledocolithiasis, 15 [11,13-
15,18,20,21,26,27,29-31,33,35,36] reported adequate
data for analysis. Figure 2 shows a scatterplot of sensitivity
vs. specificity for the 15 studies reporting choledocholith-
iasis.
Two of these studies stand out as having sensitivities
somewhat lower than the other 13 studies [11,36]. Sensi-
tivities and specificities along with 95% CI for these esti-
mates for the 15 choledocholithiasis studies are presented
in Figures 3 and 4.
The sensitivity for the 15 studies of choledocholithiasis
ranged from 0.50 to 1.00 while specificity ranged from
0.83 to 1.00. The positive likelihood ratio ranged from
5.44–47.72 and the negative likelihood ratio for the 15
studies ranged from 0.00–0.51. All of the confidence
intervals overlap, although the confidence intervals for
some studies are wide. Again two studies [11,36] have
point estimates in Figure 2 that are clearly different from
the other 13 studies, suggesting that theses two studies are
outliers. There is also some evidence of statistically signif-
icant heterogeneity between studies, (Figure 3 and 4),
which suggested that the computation of a SROC curve
was the most appropriate way to pool the results of stud-
ies.
Summary ROC curves for diagnosis of choledocholithiasis
Figure 2 also shows the parameter estimates and the
results of the Littenberg-Moses method for the estimation
of a summary best fitting ROC curve. This curve shows the
relationship between sensitivities and specificities across
the 15 studies. The non-significant result for the S coeffi-
cient estimate of 0.057 [CI: -0.25 to 0.42; p = 0.506], sug-
gests that there is no reliable statistical evidence that the
diagnostic odds ratio changes with threshold.
There is no unique joint summary estimate of sensitivity
and specificity suitable for use in clinical practice from
this plot. Table 5 shows values of sensitivity and specifi-
city off the fitted ROC curve to demonstrate the range of
values that the data are compatible with.
Assessment of effectiveness by other conditions: 
malignancy, dilatation, obstruction and stricture
For malignancy (three studies [9,18,22]), sensitivity
ranged from 0.81 to 0.94 and specificity from 0.92 to
1.00. Positive likelihood ratios ranged from 10.12 to 43
and negative likelihood ratios ranged from 0.15 to 0.21.
Although, from the results presented in Table 2 it is appar-
ent that the results for malignancy are much less reliable
than those for the other conditions presented. The sensi-
tivity for dilatation (five studies [11,12,20,25,28]) ranged
from 0.87 to 1.00 and the specificity from 0.91 to 1.00.BMC Medical Imaging 2006, 6:9 http://www.biomedcentral.com/1471-2342/6/9
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Summary of study selection Figure 1
Summary of study selection.
Total
abstracts
screened
N=311
Total full papers
screened
N= 172 (plus 4 from
other sources) 
Included studies 
N=28 (plus 1 
study of patient 
satisfaction)
Studies
excluded
on the basis 
of quality 
N=38
Studies
potentially
relevant
N=67
Rejected
full papers 
N=105
Studies
rejected at 
abstract
N=139
Studies
rejected at 
title
N=1126
Potentially relevant
studies identified and 
screened for retrieval
N=1437B
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Table 1: QUADAS quality assessment checklist applied to MRCP studies
Study 1. Patient 
spectrum
2. Selection 
criteria
3. Reference 
standard
4. Time 
period
5. Verification 
bias
6. Same 
RS
7. RS 
independent 
of IT
8. IT 
described 
in detail
9. RS 
described 
in detail
10. IT 
interpreted 
without RS
11. RS 
interpreted 
without IT
12. All 
clinical 
data
13. All 
test 
results
14. Withdrawals
Adamek[9] yes yes yes unclear no yes N/a yes no yes yes yes Yes yes
Angulo[11] yes yes unclear yes no yes N/a yes no yes yes no Yes yes
Barish[12] yes yes unclear yes no yes N/a yes no yes unclear no yes yes
Calvo[13] unclear yes unclear no no yes N/a yes unclear yes unclear yes Yes yes
Chan[14] yes unclear unclear yes no yes N/a yes unclear yes yes no Yes yes
Demartines [15] yes yes unclear unclear no yes N/a yes yes yes yes no no no
Dwerryhouse[16] unclear yes unclear no no yes N/a yes no unclear yes unclear Yes yes
Guibaud [18] yes yes unclear no no yes N/a yes no yes yes no Yes yes
Holzknecht[20] unclear yes unclear no no yes N/a yes yes yes yes unclear Yes yes
Laokpessi [21] no yes yes yes no yes N/a yes no yes unclear unclear Yes yes
Lee[22] yes yes yes no no yes N/a yes yes yes yes unclear No yes
Lomanto [23] yes unclear unclear unclear no yes N/a yes no unclear unclear unclear No no
Lomas[24] yes yes unclear yes no yes N/a yes yes no no yes Yes yes
Macaulay [25] yes unclear yes no no yes N/a yes no yes unclear no No no
Regan[26] yes unclear yes yes no yes N/a yes no yes unclear unclear Yes yes
Reinhold [27] yes yes unclear no no yes N/a yes no Yes unclear yes Yes yes
Soto 1996[28] no unclear unclear yes no yes N/a yes no Yes unclear no No unclear
Soto 2000b[29] yes yes unclear no no yes N/a yes unclear Yes yes no Yes yes
Soto 2000a[30] yes yes unclear no no yes N/a yes unclear Yes yes no Yes yes
Stiris[31] yes unclear unclear yes yes yes N/a yes no yes yes unclear Unclear unclear
Sugiyama[32] unclear no unclear no no yes N/a yes no no yes yes Yes yes
Taylor[33] yes yes unclear yes no yes N/a yes no Yes yes unclear Yes yes
Textor[34] yes unclear unclear no no yes N/a yes yes Yes unclear no Yes yes
Varghese [35] unclear unclear unclear no no yes N/a yes yes yes yes yes Yes yes
Zidi[36] yes no unclear yes no yes N/a yes yes Yes unclear no No no
RS = reference standard (ERCP); IT = index test (MRCP).
QUADAS Questions
1. Was the spectrum of patients representative of the patients who will receive the test in practice?
2. Were selection criteria clearly described?
3. Is the reference standard likely to correctly classify the target condition?
4. Is the time period between reference standard and index test short enough to be reasonably sure that the target condition did not change between the two tests?
5. Did the whole sample or a random selection of the sample, receive verification using a reference standard of diagnosis?
6. Did patients receive the same reference standard regardless of the index test result?
7. Was the reference standard independent of the index test (i.e. the index test did not form part of the reference standard?
8. Was the execution of the index test described in sufficient detail to permit replication of the test?
9. Was the execution of the reference standard described in sufficient detail to permit its replication?
10. Were the index test results interpreted without knowledge of the results of the reference standard?
11. Were the reference standard results interpreted without knowledge of the results of the index test?
12. Were the same clinical data available when test results were interpreted as would be available when the test is used in practice?
13. Were uninterpretable/intermediate test results reported?
14. Were withdrawals from the study explained?B
M
C
 
M
e
d
i
c
a
l
 
I
m
a
g
i
n
g
 
2
0
0
6
,
 
6
:
9
h
t
t
p
:
/
/
w
w
w
.
b
i
o
m
e
d
c
e
n
t
r
a
l
.
c
o
m
/
1
4
7
1
-
2
3
4
2
/
6
/
9
P
a
g
e
 
6
 
o
f
 
1
5
(
p
a
g
e
 
n
u
m
b
e
r
 
n
o
t
 
f
o
r
 
c
i
t
a
t
i
o
n
 
p
u
r
p
o
s
e
s
)
Table 2: The 25 included studies
Study Total 
number Of 
patients
Suspected 
Condition
True +ve False +ve False -ve True -ve N Sensitivity 
(95% CI)
Specificity 
(95% CI)
Likelihood ratio-
positive (95% CI)
Likelihood 
ratio-negative 
(95% CI)*
Adamek[9] 86 Abnormality 42 1 5 12 60 0.89 (0.77, 0.95) 0.92 (0.67, 0.99) 11.62 (1.76, 76.57) 0.12 (0.02, 0.76)
Adamek 81 Malignancy 22 0 5 33 60 0.81 (0.63, 0.92) 1.00 (0.90, 1.00) 54.64 (3.47, 861.18) 0.20 (0.01, 3.14)
Angulo[11] 73 Normal 19 2 3 46 70 0.86 (0.67, 0.95) 0.96 (0.86, 0.99) 20.73 (5.28, 81.31) 0.14 (0.04, 0.56)
Angulo 70 dilitation CBD 38 2 3 27 70 0.93 (0.81, 0.97) 0.93 (0.78, 0.98) 13.44 (3.52, 51.33) 0.08 (0.02, 0.30)
Angulo 72 Obstruction 37 3 0 39 79 1.00 (0.91, 1.00) 0.91 (0.76, 0.97) 11.00 (3.74, 32.36) 0.00
Angulo 70 Choledocholithiasis 5 1 5 59 70 0.50 (0.24, 0.76) 0.98 (0.91, 1.00) 30.00 (3.90, 230.73) 0.51 (0.07, 3.91)
Angulo 70 PSC 19 1 4 46 70 0.83 (0.63, 0.93) 0.98 (0.89, 1.00) 38.83 (5.53, 272.37) 0.18 (0.03, 1.25)
Barish[12] 29 Dilitation 13 0 2 6 21 0.87 (0.62, 0.96) 1.00 (0.61, 1.00) 11.81 (0.81, 172.17) 0.17 (0.01, 2.45)
Calvo[13] 61 Choledocholithiasis 29 2 3 10 44 0.91 (0.76, 0.97) 0.83 (0.55, 0.95) 5.44 (1.53, 19.36) 0.11 (0.03, 0.40)
Chan[14] 47 Choledocholithiasis 18 4 1 22 45 0.95 (0.75, 0.99) 0.85 (0.66, 0.94) 6.16 (2.48, 15.26) 0.06 (0.03, 0.15)
Demartines[15] 40 Choledocholithiasis 19 2 0 19 40 1.00 (0.83, 1.00) 0.90 (0.71, 0.97) 10.50 (2.81, 39.24) 0.00
Dwerryhouse[16] 40 Choledocholithiasis 7 2 1 28 38 0.88 (0.53, 0.98) 0.93 (0.79, 0.98) 13.13 (3.35, 51.36) 0.1 (0.03, 0.52)
Guibaud[18] 79 Obstruction 72 0 7 47 126 0.91 (0.83, 0.96) 1.00 (0.92, 1.00) 87.00 (5.52, 1372.23) 0.09 (0.01, 1.49)
Guibaud Choledocholithiasis 26 2 6 92 126 0.81 (0.65, 0.91) 0.98 (0.93, 0.99) 38.19 (9.60, 151.97) 0.19 (0.05, 0.76)
Guibaud Malignancy 12 2 2 110 126 0.86 (0.60, 0.96) 0.98 (0.94, 1.00) 48.00 (11.96, 192.72) 0.15 (0.04, 0.58)
Holzknecht[20] 61 Choledocholithiasis 12 3 2 46 63 0.86 (0.60, 0.96) 0.94 (0.83, 0.98) 14.00 (4.58, 42.78) 0.15 (0.05, 0.47)
Holzknecht Dilatation 32 2 2 26 62 0.94 (0.81, 0.98) 0.93 (0.77, 0.98) 13.18 (3.46, 50.23) 0.06 (0.02, 0.24)
Holzknecht Stenosis 31 3 5 22 61 0.86 (0.71, 0.94) 0.88 (0.70, 0.96) 7.18 (2.46, 20.91) 0.16 (0.05, 0.46)
Holzknecht Overall 43 3 4 12 62 0.91 (0.80, 0.97) 0.80 (0.55, 0.93) 4.57 (1.66, 12.63) 0.11 (0.04, 0.29)
Laokpessi[21] 101 Choledocholithiasis 105 0 8 34 147 0.93 (0.87, 0.96) 1.00 (0.90, 1.00) 64.78 (4.13, 1015.86) 0.08 (0.00, 1.19)
Lee[22] 46 Malignancy 17 2 4 23 46 0.81 (0.60, 0.92) 0.92 (0.75, 0.98) 10.12 (2.64, 38.86) 0.21 (0.05, 0.79)
Lomanto[23] 136 Choledocholithiasis 22 0 2 38 62 0.92 (0.74, 0.98) 1.00 (0.91, 1.00) 70.20 (4.46, 1105.97) 0.10 (0.01, 1.60)
Lomas[24] 76 Choledocholithiasis 9 2 0 58 69 1.00 (0.70, 1.00) 0.97 (0.89, 0.99) 30.00 (7.68, 117.19) 0.00
Lomas Stricture 19 1 0 49 69 1.00 (0.83, 1.00) 0.98 (0.90, 1.00) 50.00 (7.18, 348.04) 0.00
Macaulay[25] 29 Dilatation 18 1 0 10 29 1.00 (0.82, 1.00) 0.91 (0.62, 0.98) 11.00 (1.70, 71.28) 0.00
Regan[26] 23 Choledocholithiasis 14 1 1 7 23 0.93 (0.70, 0.99) 0.88 (0.53, 0.98) 7.47 (1.19, 46.94) 0.08 (0.01, 0.48)
Reinhold[27] 110 Obstruction 69 0 7 34 110 0.91 (0.82, 0.95) 1.00 (0.90, 1.00) 63.18 (4.03, 991.27) 0.10 (0.01, 1.55)
Reinhold Choledocholithiasis 27 3 3 77 110 0.90 (0.74, 0.97) 0.96 (0.90, 0.99) 24.00 (7.86, 73.31) 0.10 (0.03, 0.32)
Soto 1996[28] 46 Dilatation 26 1 1 16 44 0.96 (0.82, 0.99) 0.94 (0.73, 0.99) 16.37 (2.44, 109.77) 0.04 (0.01, 0.26)
Soto 2000[29] 57 Choledocholithiasis 23 1 1 24 49 0.96 (0.80, 0.99) 0.96 (0.80, 0.99) 23.96 (3.50, 163.78) 0.04 (0.01, 0.30)
Soto 2000[30] 51 Choledocholithiasis 25 0 1 25 51 0.96 (0.81, 0.99) 1.00 (0.87, 1.00) 49.11 (3.15, 765.62) 0.06 (0.00, 0.88)
Stiris[31] 50 Choledocholithiasis 28 1 4 17 50 0.88 (0.72, 0.95) 0.94 (0.74, 0.99) 15.75 (2.33, 106.28) 0.13 (0.02, 0.89)
Sugiyama[32] 159 anamalous PBJ 9 0 2 148 159 0.82 (0.52, 0.95) 1.00 (0.97, 1.00) 235.92 (14.60, 3811.82) 0.21 (0.01, 3.38)
Taylor[33] 146 Choledocholithiasis 45 9 1 74 129 0.98 (0.89, 1.00) 0.89 (0.81, 0.94) 9.02 (4.86, 16.74) 0.02 (0.01, 0.05)
Taylor Stricture 12 1 0 118 131 1.00 (0.76, 1.00) 0.99 (0.95, 1.00) 118.00 (16.76, 830.78) 0.00
Textor[34] 150 PSC 29 1 4 108 142 0.88 (0.73, 0.95) 0.99 (0.95, 1.00) 95.79 (13.56, 676.70) 0.12 (0.02, 0.86)
Varghese[35] 191 Choledocholithiasis 31 3 3 154 191 0.91 (0.77, 0.97) 0.98 (0.95, 0.99) 47.72 (15.48, 147.06) 0.09 (0.03, 0.28)
Zidi[36] 70 Choledocholithiasis 28 0 21 21 70 0.57 (0.43, 0.70) 1.00 (0.85, 1.00) 25.08 (1.60, 392.61) 0.44 (0.03, 6.89)
* With likelihood ratios of zero, the data are unsuitable for the calculation of 95% confidence intervals.B
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Table 3: Study characteristics
Study, country Sample selection Comparison (type of MRCP and 
reference tests used)
Description of patients and procedures; study 
period
Time between ERCP and 
MRCP
Adamek et al, 1998; 
Germany[9]
Not reported RARE and HASTE MRCP were compared 
with ERCP
86 patients entered the study; 8 were excluded due 
to biliary-enteric anastomoses, of the remaining 78, 
16 had unsatisfactory ERCP, 2 had unsatisfactory 
MRCP (claustrophobia) leaving 60 patients who had 
both January-December 1996
Not reported
Angulo et al, 2000; USA[11] Not reported Fast spin echo pulse sequence compared 
with ERCP and PTC
Initially 74, 1 did not receive MRCP due to 
claustrophobia, 73 had MRCP, 68 had ERCP, 2 had 
PTC and 3 had neither Study period not stated
MRCP performed within 24 
hours preceding the scheduled 
ERCP
Barish et al, 1995; USA[12] Random selection from 
referrals
3D TSE MRCP compared with ERCP and 
PTC
30 patients initially selected, one patient did not 
receive MRCP due to the presence of ascitic fluid in 
the upper abdomen; three had PTC due to failed 
ERCP, 8 of the 29 patients did not have ERCP or PTC 
Study period not reported
ERCP was performed 8 hours 
after MRCP
Calvo et al, 2002; Spain[13] Not reported Two HASTE sequences MRCP compared 
with ERCP
116 patients with suspected biliopancreatic pathology 
initially, of these 61 patients were selected with 
suspected choledocholithiasis, failure in one patient 
for ERCP November 1996-February 1998
MRCP within 72 hours before 
ERCP
Chan et al, 1996; Hong 
Kong[14]
Consecutive sample T2-weighted turbo spin-echo sequence 
(non-breath-hold, fat-suppressed) MRCP 
compared with ERCP
47 had MRCP, 45 had ERCP (two failures) May-
August 1995
ERCP within 5 hours after MRCP
Demartines et al, 2000; 
Switzerland[15]
Not reported 3 acquisition techniques of MRCP were 
used including T2/T1 weighted, single-shot 
turbo spin echo and half-Fourier 
acquisition single-shot turbo spin echo 
heavy sequence compared with ERCP 
(high-risk patients) or intraoperative 
cholangiography (moderate risk patients)
40 patients received ERCP and MRCP and 30 
received IOC and MRCP April 1997-September 1998
Not reported
Dwerryhouse et al, 1998; 
UK[16]
Not reported T2 weighted TSE with non-breath-holding 
MRCP compared with ERCP and POC
Initially 405 patients who underwent laparoscopic 
cholecystectomy, of these 278 had no known risk 
factors for CB stones, 87 underwent early ERCP and 
were excluded. 40 patients with risk factors for CBD 
stones underwent MRCP. 2 patients had failed MRCP 
due to claustrophobia, ERCP was unsuccessful in 4 
patients who then had peroperative cholangiography. 
February 1996 – January 1998
All patients underwent ERCP 
within 1 week after ERCP
Guibaud et al, 1995; 
Canada[18]
Consecutive 2D FSE MRCP compared with ERCP, 
PTC, T-tube cholangiography, surgery and 
autopsy
198 patients initially of which 72 were excluded due 
to no proof of bile duct obstruction (n = 42), 
unsuccessful ERCP (n = 12), unsuccessful MRCP due 
to claustrophobia (n = 6), inadequate ERCP (n = 10) 
or MRCP (n = 2) leaving 126 patients September 
1992-March 1993
Time between MRCP and final 
diagnosis was less than 6 hours in 
105 cases, less than 1 week in 15 
cases and more than 1 week in 
six cases
Holzknecht et al, 1998; 
Germany[20]
Consecutive sample RARE and half-Fourier RARE MRCP 
compared with ERCP
66 patients were eligible, 2 were excluded because of 
pacemakers, 3 had failed ERCP after MRCP leaving 61 
patients who had both MRCP and ERCP June 1995 to 
April 1996
MRCP performed before ERCP 
(patients were due to have ERCP 
within the next 2 days)B
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Laokpessi et al, 2001; 
France[21]
Consecutive sample FSE and T2 heavily weighted single-shot 
FSE sequences with fat suppression MRCP 
compared with ERCP or intraoperative 
cholangiography (IOC)
Initially 166 inpatients but only 147 patients had 
MRCP, of these 101 had ERCP and 45 had IOC and 
cholecystectomy. Those in group receiving ERCP had 
a past history of cholecystectomy or had a high 
surgical or anaesthetic risk. 21 removed from study 
for: refusal to sign protocol (n = 3), refusal to 
undergo MRCP (n = 4) or ERCP (n = 7), excessive 
time between MRCP and final diagnosis (n = 7) 
November 1997-December 1999
Average time between MRCP 
and final diagnosis 10 hours 
(range 3–48 hours) if longer than 
48 hours between MRCP and 
final diagnosis, patients were 
removed from the study
Lee et al, 1997; South 
Korea[22]
Consecutive sample 3D steady-state free-precession MRCP 
compared with ERCP
71 patients of which 25 were excluded (8 because 
ERCP was not performed, 15 who were evaluated for 
intrahepatic stones, 1 for peripheral type of 
intrahepatic cholangiocarcinoma, 1 suspected 
mucinous ductal ectasia of the pancreas) leaving 46 
patients who had both MRCP and ERCP January-
March 1995
33 patients had MRCP before 
ERCP ranging from 6 hours to 5 
days. The remaining 31 patients 
had ERCP first ranging from 3 to 
16 days
Lomanto et al, 1997; Italy[23] Not reported T2 weighted TSE sequence MRCP 
compared with ERCP and PTC
136 patients referred for MRCP, of these 62 had 
MRCP for choledocholithiasis, (the other 74 were: 48 
for stenosis of the biliary tract, 15 with previous 
hepaticojejunostomy and choledochojejunostomy and 
11 with chronic pancreatitis) 60 of these patients had 
ERCP and 2 had PTC September 1994-October 1995
Not reported
Lomas et al, 1999; UK[24] Not reported Hybrid four-shot RARE (FSE) sequence 
and a single-shot half Fourier RARE 
sequence compared with ERCP
76 referrals, of these 2 did not have MRCP (one was 
obese and one was claustrophobic), 5 did not have 
ERCP (1 died, 1 refused and in 3 patients the 
operator was unable to cannulate the common bile 
duct) leaving 69 referrals in 66 patients 18 month 
period, dates not stated
MRCP took place first within 4 
hours of ERCP
Macaulay, et al, 1995; 
USA[25]
Sequential T2-weighted TSE MRCP (non-breath 
hold) compared with ERCP, PTC and IOC
28 patients initially had MRCP, 24 patients had 28 
direct cholangiographic studies (21 had ERCP, 6 had 
PTC and 1 had IOC) Study period not reported.
ERCP took place within 1–4 
hours in 15 patients, 4 were 
within 5–7 days after MRCP and 
1 was 11 days before and 
another 109 days before MRCP, 
all PTC studies were within 2 
days after MRCP and the 1 IOC 
preceded MRCP by 5 days.
Regan et al, 1996; USA[26] Not reported HASTE MRCP compared with ERCP and 
sonography
26 patients, 2 had unsuccessful ERCP and one did not 
have MRCP due to claustrophobia leaving 23 patients
MRCP was performed just 
before ERCP in 18 patients and 
within 24 hours in 5 patients
Reinhold et al, 1998; 
Canada[27]
Consecutive FSE MRCP compared with ERCP, IOC and 
surgery
Initially 159 patients of which 49 were excluded due 
to the following reasons: 34 due to lack of diagnosis, 
10 due to unsuccessful ERCP, 3 due to unsuccessful 
MRCP due to claustrophobia, inadequate ERCP (n = 
1) or MRCP (n = 1) leaving a sample of 110 patients. 
101 patients had ERCP, 2 had IOC and 7 had surgery. 
5 month study period, dates not reported
MRCP was performed first and 
ERP or equivalent was less than 6 
hours later in 97 patients, less 
than 1 week in 7 patients and 
more than 1 week in 6 patients
Soto et al, 1996; USA[28] Randomly recruited 3D FSE MRCP compared with ERCP and 
PTC
46 patients, 7 of whom were included in Barish et al, 
199558, 45 had ERCP and 1 had PTC May 1994-April 
1995
ERCP/PTC within 24 hours after 
MRCP
Table 3: Study characteristics (Continued)B
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Soto et al, 2000a; 
Columbia[30]
Not reported Breath hold, single shot half-Fourier rapid 
acquisition and non-breath-hold 3D FSE 
MRCP compared with ERCP, CT and 
oral-contrast enhanced CT 
cholangiography
Initially 68 patients, 12 did not meet inclusion or 
exclusion criteria, 2 did not have MRCP because of 
claustrophobia, in 3 ERCP was not attempted or 
completed leaving 51 patients who had all 4 studies. 
April 1998-March 1999
MRCP performed within 48 
hours before ERCP
Soto et al, 2000b; 
Columbia[29]
Not reported 3D fast SE, Single section Half-Fourier 
RARE and multi-section half-Fourier 
RARE MRCP compared with ERCP
Initially 59 patients, 10 were excluded due to the 
following reasons: 2 due to MRCP contraindications, 
4 because 1 or more of the 3 MRCP sequences could 
not be completed, and 4 because ERCP could not be 
completed August 1997-May 1998
MRCP was completed before 
ERCP within 72 hours
Stiris et al, 2000; Norway[31] Consecutive sample HASTE fat suppressed breath-hold MRCP 
compared with ERCP
50; all patients had both techniques; study period not 
stated
MRCP performed first followed 
by ERCP within 12 hours
Sugiyama et al, 1998; 
Japan[32]
Non consecutive HASTE MRCP compared with ERCP 187 patients were recruited, 19 underwent only 
cholangiography or pancreatography on ERCP, in 8 
the common channel could not be identified clearly 
and there was failure of cannulation in 2 patients 
leaving 159 patients with common bile duct, main 
pancreatic duct and common channel depicted June 
1994-August 1996
MRCP was 0 to 14 days before 
ERCP
Taylor et al, 2002; 
Australia[33]
Consecutive sample HASTE MRCP compared with ERCP, PTC 
or surgery
Initially 149 procedures (146 patients), MRCP 
unsuccessful in 8 due to claustrophobia and in 1 
patient due to poor image quality, 5 were excluded 
because MRCP was more than 24 hours before 
ERCP, in 20 ERCP was unsuccessful (3 had 
subsequent ERCP, 2 had surgery and 2 had PTC and 
were included). In two patients ERCP and MRCP 
were both unsuccessful, leaving 129 patients who had 
both MRCP and ERCP (or equivalent). November 
1998-December 1999
MRCP was performed within 24 
hours before ERCP
Textor et al, 2002; 
Germany[34]
Consecutive sample 3D T2 weighted FSE MRCP compared 
with ERCP
150 patients initially, of which 146 had successful 
MRCP, 3 patients with PSC had unsuccessful ERCP 
and another failed due to a bilidigestive anastomosis 
January 1996-December 2000
ERCP was performed 1–14 days 
before MRCP (mean 3.2 days)
Varghese et al, 2000; 
Ireland[35]
Consecutive sample T2 weighted 2D multi-slice FSE MRCP 
compared with ERCP, PTC or IOC
256 patients initially, 64 of which were excluded 
because ultrasound report or ERCP hard-copy images 
were not available (n = 30), direct cholangiography 
was not performed after failed ERCP (n = 22), MRCP 
not performed due to contraindications (n = 5), 
MRCP images were of non-diagnostic quality (n = 7), 
resulting in 191 patients [of these 34 had 
choledocolithiasis diagnosed by ERCP (n = 29), IOC 
(n = 3) and PTC (n = 2)] 18 month period, dates not 
stated
MRCP was performed before 
ERCP within a period of 4 hours 
to 2 weeks (mean 18 hours)
Zidi et al, 1999; France[36] Consecutive sample Non breath-hold fat suppressed TSE 
MRCP compared with ERCP (with or 
without sphincterotomy), 
endosonography or IOC
70 inpatients were included, 63 had ERCP, 5 had 
sonography and 2 had IOC 12 month period, dates 
not reported
MRCP performed within 12 
hours before ERCP
Table 3: Study characteristics (Continued)BMC Medical Imaging 2006, 6:9 http://www.biomedcentral.com/1471-2342/6/9
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Scatterplot of sensitivity vs. 1-specificity of MRCP test for diagnosing choledocholithiasis with Littenberg-Moses Summary ROC  curve and actual data (n = 15 studies) Figure 2
Scatterplot of sensitivity vs. 1-specificity of MRCP test for diagnosing choledocholithiasis with Littenberg-Moses Summary ROC 
curve and actual data (n = 15 studies).
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For obstruction (three studies [11,18,27]), sensitivity
ranged from 0.91 to 1.00 and specificity from 0.91 to
1.00. Sensitivity for stricture (two studies [24,33]) was
1.00 and specificity ranged from 0.98 to 0.99.
Adverse events and satisfaction with procedures
None of the 28 studies reported any adverse events associ-
ated with MRCP. Six studies [9,11,13,27,31,34] reported
adverse effects associated with ERCP, including pancreati-
tis, bleeding and pain. Two [10,15] reported that no
adverse events had occurred and 20 gave no information
at all regarding adverse events. Claustrophobia associated
with MRCP was reported in ten studies
[9,11,16,18,19,24,26,27,30,33].
The separate study [37] dealing with patient satisfaction
found that most patients preferred MRCP, although there
were still some patients who preferred ERCP. Almost half
of the patients in this small study complained of claustro-
phobia associated with MRCP, although very few (5.9%)
refused MRCP for this reason.
Discussion
This systematic review shows that there is evidence that
MRCP stands up well to comparisons with diagnostic
Forest plot of estimated sensitivities of MRCP test for diagnosing choledocholithiasis (n = 15 studies) Figure 3
Forest plot of estimated sensitivities of MRCP test for diagnosing choledocholithiasis (n = 15 studies).
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ERCP, for the diagnosis of many biliary abnormalities.
From the small number of comparative studies with final
diagnosis, it appears that ERCP is an adequate reference
standard for choledocholithiasis with sensitivities and
specificities above 89%, however the results for malig-
nancy were much less reliable. The limited evidence on
patient satisfaction shows that patients prefer MRCP to
diagnostic ERCP. The results of our review are similar to
those found by Romagnuolo et al [38] who in their meta-
analysis showed high levels of sensitivity and specificity
for demonstrating the level and presence of biliary
obstruction.
The main advantage of MRCP is that diagnostic ERCP may
be associated with significant morbidity and mortality
[39]. Reported complication rates of diagnostic ERCP are
Forest plot of estimated specificities of MRCP test for diagnosing choledocholithiasis (n = 15 studies) Figure 4
Forest plot of estimated specificities of MRCP test for diagnosing choledocholithiasis (n = 15 studies).
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5–6% and mortality figures range from 0.01% (36) to
0.89% [40]. Therapeutic ERCP has a complication rate of
4–10% [41]. Diagnostic ERCP has the potential to allow a
therapeutic procedure to be performed immediately, but
its indiscriminate use will result in an increasing propor-
tion of patients in whom such intervention is found to be
unnecessary. If preliminary tests, such as EUS or com-
puted tomography, clearly indicate the need for therapeu-
tic ERCP, then the use of diagnostic MRCP is probably
unwarranted. Those patients with a high probability of
choledocholethiasis on the basis of EUS investigations
usually proceed directly to ERCP. These issues are elabo-
rated in Bravo et al [42].
There were no reported adverse events associated with
MRCP, other than claustrophobia. However, in certain cir-
cumstances MRCP cannot be performed due to contrain-
dications to Magnetic Resonance Imaging, e.g. in patients
with cardiac pacemakers or cochlear implants. Severe
claustrophobia may make patients intolerant of the proce-
dure.
Limitations of this study
Overall the quality of the studies was variable. In only one
study did all selected patients have both MRCP and diag-
nostic ERCP. The reasons why all patients in the other
studies did not receive both investigations were not clear.
In 21 of the studies, the stated comparison was with
ERCP, while in the other seven studies, comparison was
with final diagnosis; making comparisons between all
studies difficult.
We can consider three ways of categorising a patient: their
true condition, the diagnosis and the test results [43]. We
have calculated the sensitivity and specificity of MRCP in
relationship to diagnosis by ERCP, but we do not neces-
sarily know that the diagnosis is always correct. ERCP is
not a perfect gold standard, so differences in diagnosis
between MRCP and ERCP may not be due to MRCP giving
an incorrect result, but rather to ERCP giving an incorrect
result. So we have evaluated MRCP's ability to predict the
diagnosis of choledocholithiasis rather than the patient's
true disease status. So any errors in the ERCP reference test
may lead to either underestimates or overestimates of
MRCP's accuracy.
There are several problems associated with using sum-
mary ROC curves. For example, although the production
of a summary ROC curve does allow the computation of
a summary estimate of diagnostic performance, the results
cannot be directly applied to clinical practice.
Our results indicate that MRCP is accurate for diagnosis of
biliary abnormalities compared to diagnostic ERCP,
within the limits of the available data. Good quality stud-
Table 5: Estimates of diagnostic odds ratio (DOR), sensitivity and 
specificity from the regression of D = a + bS for Littenberg-Moses 
Summary ROC curve for MRCP test diagnosis of 
choledocholithiasis (n = 15 studies) for a range of values of 
diagnostic threshold (S)
Diagnostic Odds 
Ratio (DOR)
Sensitivity Specificity
mean S 193.22 0.91 0.95
min S 144.79 0.61 0.99
max S 239.34 0.97 0.87
Table 4: Studies comparing MRCP and ERCP with final diagnosis
Study Definition of Final 
diagnosis
Sensitivity Specificity
MRCP vs. final 
diagnosis
ERCP vs. final 
diagnosis*
MRCP vs. final 
diagnosis
ERCP vs. final 
diagnosis*
Adamek[9] ERCP plus histological 
findings or follow-up
42/47 for any 
abnormality
0.89 (CI: 0.77–0.95)
22/27 for malignancy
0.81 (CI: 0.63–0.92)
0.91 for any 
abnormality
0.93 for malignancy
12/13
0.92 (CI: 0.67–0.99) for 
any abnormality
33/33
1.00 (CI: 0.90–1.00) for 
malignancy
0.92 for any 
abnormality
0.94 for malignancy
Laokpessi[21] Stone extraction with 
ERCP or IOC
105/113
0.93 (CI: 87–0.96) for 
Choledocholithiasis
78/81
0.95 (CI: 0.87–0.98)
34/34
1.00 (CI: 0.90–1.00)
19/19
1.00 (CI: 0.79–1.00)
Lee[22] ERCP plus surgical findings 17/21 for malignancy
0.81 (CI: 0.60–0.92)
15/21
0.71 (CI: 0.50–0.86)
23/25
0.92 (CI: 0.75–0.98)
23/24
0.96 (CI: 0.80 to 0.99)
Regan[26] ERCP, endoscopic balloon 
or basket extraction or 
surgical removal of stones
14/15
0.93 (CI: 0.70–0.99) 
for choledocholithiasis
15/15
1.00 (CI: 0.80–1.00)
7/8
0.88 (CI: 0.53–0.98)
8/8
1.00 (CI: 0.68–1.00)
*Raw data was not reported in some studies, therefore it is not clear whether are not the two groups (MRCP vs. final diagnosis and ERCP vs. final 
diagnosis) are directly comparable.BMC Medical Imaging 2006, 6:9 http://www.biomedcentral.com/1471-2342/6/9
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ies, particularly randomised controlled trials (we found
no comparative clinical trials of the two techniques in our
review), are needed comparing MRCP with diagnostic
ERCP to final diagnosis, stating inclusion/exclusion crite-
ria and relevant patient characteristics. These studies need
to include the full range of target conditions, in particular
the differentiation of benign and malignant strictures and
the impact on management and outcome. Studies are also
needed comparing MRCP with final diagnosis where
ERCP is unsuitable or impossible. More research is also
needed in the area of patient satisfaction and ways to
reduce problems with claustrophobia.
Conclusion
MRCP is a comparable diagnostic investigation in com-
parison to ERCP for diagnosing biliary abnormalities.
Results were particularly favourable for choledocholethia-
sis and less so for malignancy. Limited information on
patient satisfaction found that patients prefer MRCP to
ERCP. The use of MRCP in suitable patients reduces the
need for diagnostic ERCP which is associated with signif-
icant morbidity and mortality.
Abbreviations
DOR diagnostic odds ratio
ERCP endoscopic retrograde cholangiopancreatography
L-M Littenberg and Moses
MRCP magnetic resonance cholangiopancreatography
ROC Receiver Operating Characteristic curve
SROC Summary Receiver Operating Characteristic curve
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